Neurovasx, Inc.

Calculating rank

USPTO Granted Patents = 6

% Expired Patents = 16.7

Forward Citations = 703

Loading Chart...

4 inventors (with patents filed for the assignee):

Robert Boock (3 out of 4 patents)

Jeffrey A Lee (3 out of 10 patents)

Steven J Ferry (1 out of 11 patents)

4. DeLois Marlene Ferry (1 out of 1 patent)

6 patents: Sort by Forward Citations

1. 10342547 - Guidewire/ partial occluder for intraluminal travel (2019-07-09),

2. 6620179 - Clot disrupting wire/catheter assembly (2003-09-16),

3. 6322572 - Thrombus macerator catheter (2001-11-27),

4. 6312421 - Aneurysm embolization material and device (2001-11-06),

5. 6309367 - Aneurysm shield (2001-10-30),

6. 5954737 - Thrombus macerator catheter (1999-09-21),

Company Overview

Neurovasx, Inc. is a medical device company focused on the development and commercialization of innovative therapies for the treatment of neurovascular disorders. The company's flagship product is the cPAX Aneurysm Treatment System, a minimally invasive device designed to treat intracranial aneurysms. Neurovasx is dedicated to improving patient outcomes and revolutionizing the standard of care in neurovascular medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

6 Patents

#6 in Excelsior, MN

#1,240 in Minnesota

#45,007 in US

Excelsior, MN, United States of America

Neurovasx, Inc.

Forward Citations = 703

4 inventors:

Robert Boock (3 out of 4 patents)

Jeffrey A Lee (3 out of 10 patents)

Steven J Ferry (1 out of 11 patents)

4. DeLois Marlene Ferry (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neurovasx, Inc.. Retrieved from https://idiyas.com/company/neurovasx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]